Anar al contingut
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • ACTIVITY OF THE PAN-HER TYROSI...
  • Citar
  • Enviar aquest missatge de text
  • Enviar per correu electrònic aquest
  • Imprimir
  • Exportar registre
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enllaç permanent
ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING

ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING

Dades bibliogràfiques
Autors principals: Blackhall, F, Gadgeel, S, Reckamp, K, Talbot, D, Barrios, C, Krzakowski, M, Liang, J, O'Connell, J
Format: Journal article
Publicat: 2012
  • Fons
  • Descripció
  • Ítems similars
  • Visualització del personal

Ítems similars

  • Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
    per: Ramalingam, S, et al.
    Publicat: (2012)
  • Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
    per: Justin P Williams, et al.
    Publicat: (2014-01-01)
  • Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
    per: Jinyao Zhang, et al.
    Publicat: (2021-12-01)
  • Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
    per: Lavacchi D, et al.
    Publicat: (2019-09-01)
  • Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
    per: Xingxiang Pu, et al.
    Publicat: (2023-10-01)

Opcions de cerca

  • Historial de cerca
  • Cerca avançada

Trobar-ne més

  • Explorar el catàleg
  • Explorar alfabèticament
  • Explora canals
  • Bibliografia recomanada
  • Nous ítems

Necessites ajuda?

  • Consells de cerca
  • Pregunteu al bibliotecari
  • FAQs